Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4W2AC
|
|||
| Drug Name |
NX-13
|
|||
| Synonyms |
Amelenodor; Amelenodor [INN]; NX-13 free base; DVH35H3HDB; 2389235-01-0; NX-13; UNII-DVH35H3HDB; 1,3,5-Tris((6-methylpyridin-2-yl)oxy)benzene; 2,2',2''-(1,3,5-Benzenetriyltris(oxy))tris(6-methylpyridine; 2,2',2''-(Benzene-1,3,5-triyltris(oxy))tris(6-methylpyridine); Pyridine, 2,2',2''-(1,3,5-benzenetriyltris(oxy))tris(6-methyl-; 2,2',2''-[1,3,5-Benzenetriyltris(oxy)]tris[6-methylpyridine; 2,2',2''-[benzene-1,3,5-triyltris(oxy)]tris(6-methylpyridine); Pyridine, 2,2',2''-[1,3,5-benzenetriyltris(oxy)]tris[6-methyl-; CHEMBL5095087; SCHEMBL22061849; AKOS040756180
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [1] | |
| Company |
Landos Biopharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H21N3O3
|
|||
| Canonical SMILES |
CC1=NC(=CC=C1)OC2=CC(=CC(=C2)OC3=CC=CC(=N3)C)OC4=CC=CC(=N4)C
|
|||
| InChI |
InChI=1S/C24H21N3O3/c1-16-7-4-10-22(25-16)28-19-13-20(29-23-11-5-8-17(2)26-23)15-21(14-19)30-24-12-6-9-18(3)27-24/h4-15H,1-3H3
|
|||
| InChIKey |
OPUQKVNCXCWRLR-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NLR family member X1 (NLRX1) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05785715) A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Phase 2 Induction Study With Long-Term Extension to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants w/ Moderate to Severe Ulcerative Colitis. U.S.National Institutes of Health. | |||
| REF 2 | Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1. Drug Chem Toxicol. 2022 Jan;45(1):209-214. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.